These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9436933)

  • 21. Induction of apoptosis by idarubicin: how important is the plasma peak?
    Gieseler F; Clark M; Stiebeling K; Puschmann M; Valsamas S
    Int J Clin Pharmacol Ther; 2000 Apr; 38(4):217-21. PubMed ID: 10783832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and toxicity of idarubicin in the rat.
    Kuhlmann O; Hofmann S; Weiss M
    Eur J Drug Metab Pharmacokinet; 2001; 26(4):215-9. PubMed ID: 11808862
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of idarubicin and daunorubicin and their main metabolites regarding intracellular uptake and effect on sensitive and multidrug-resistant HL60 cells.
    Tidefelt U; Prenkert M; Paul C
    Cancer Chemother Pharmacol; 1996; 38(5):476-80. PubMed ID: 8765443
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study.
    Kroschinsky F; Schleyer E; Renner U; Schimming C; Schimmelpfennig C; Bornhäuser M; Illmer T; Trümper L; Ehninger G; Schaich M
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):61-7. PubMed ID: 12955471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of idarubicin (4-demethoxydaunorubicin; IMI-30; NSC 256439) following intravenous and oral administration in patients with advanced cancer.
    Gillies HC; Herriott D; Liang R; Ohashi K; Rogers HJ; Harper PG
    Br J Clin Pharmacol; 1987 Mar; 23(3):303-10. PubMed ID: 3471265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis.
    Hempel G; Haberland S; Schulze-Westhoff P; Möhling N; Blaschke G; Boos J
    J Chromatogr B Biomed Sci Appl; 1997 Sep; 698(1-2):287-92. PubMed ID: 9367219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose consolidation chemotherapy with Idarubicin and alkylating agents following induction with gemcitabine-epirubicin-paclitaxel in metastatic breast cancer: a dose finding study.
    Bengala C; Danesi R; Guarneri V; Pazzagli I; Donati S; Favre C; Fogli S; Biadi O; Innocenti F; Del Tacca M; Mariani M; Conte PF
    Bone Marrow Transplant; 2003 Feb; 31(4):275-80. PubMed ID: 12621462
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
    Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
    Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
    Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
    Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin.
    Corsini C; Ghielmini M; Mancuso P; Tealdo F; Paolucci M; Zucchetti M; Ferrucci PF; Cocorocchio E; Mezzetti M; Mori A; Riggi M; D'Incalci M; Martinelli G
    Br J Cancer; 2000 Feb; 82(3):524-8. PubMed ID: 10682659
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pharmacokinetics of new anthracyclines].
    Robert J
    Bull Cancer; 1988; 75(2):167-74. PubMed ID: 3282579
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Idarubicin and idarubicinol effects on breast cancer multicellular spheroids.
    Orlandi P; Barbara C; Bocci G; Fioravanti A; Di Paolo A; Del Tacca M; Danesi R
    J Chemother; 2005 Dec; 17(6):663-7. PubMed ID: 16433198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Idarubicin: a brief overview on pharmacology and clinical use.
    Borchmann P; Hübel K; Schnell R; Engert A
    Int J Clin Pharmacol Ther; 1997 Feb; 35(2):80-3. PubMed ID: 9147715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the intracellular pharmacokinetics of daunorubicin and idarubicin in patients with acute leukemia.
    Tidefelt U; Sundman-Engberg B; Paul C
    Leuk Res; 1994 Apr; 18(4):293-7. PubMed ID: 8170171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
    Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
    Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determination of idarubicin and idarubicinol in rat plasma using reversed-phase high-performance liquid chromatography and fluorescence detection.
    Kuhlmann O; Hofmann S; Weiss M
    J Chromatogr B Biomed Sci Appl; 1999 May; 728(2):279-82. PubMed ID: 10406213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture.
    Kuffel MJ; Reid JM; Ames MM
    Cancer Chemother Pharmacol; 1992; 30(1):51-7. PubMed ID: 1586980
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A pharmacokinetic study of idarubicin in Japanese patients with malignant lymphoma: relationship with leukocytopenia and neutropenia.
    Fukushima T; Yamashita T; Goto N; Ueda T; Okabe KI; Kuraishi Y; Ohno R; Urabe A; Ogawa M
    Int J Hematol; 2001 Oct; 74(3):297-302. PubMed ID: 11721966
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.
    Pui CH; de Graaf SS; Dow LW; Rodman JH; Evans WE; Alpert BS; Murphy SB
    Cancer Res; 1988 Sep; 48(18):5348-52. PubMed ID: 3165708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of the transdermal bioavailability of a newly developed diclofenac sodium patch in comparison with a reference preparation.
    Gschwend MH; Martin W; Arnold P; Verdun MO; Cambon N; Frentzel A; Scheiwe W
    Arzneimittelforschung; 2005; 55(7):403-13. PubMed ID: 16080280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.